STCube Confirms Pancreatic Cancer Treatment Efficacy, Establishes Low-Molecular Immuno-Oncology Compound... "Technology Export Discussions Underway"

[Asia Economy Reporter Hyunseok Yoo] STCube, a bio company developing immune checkpoint inhibitors, disclosed on the 24th the research results on a new small molecule immune checkpoint inhibitor ‘SD133’ that inhibits the function of ‘STT-011,’ an immune regulatory substance expressed in pancreatic cancer and various other cancer types.

‘SD133,’ jointly developed by STCube and researchers from the Lombardi Cancer Center at Georgetown University in the United States, demonstrated immune regulatory function and anticancer therapeutic effects in various pancreatic cancer animal model experiments.

‘STT-011’ is a substance expressed in stromal cells of pancreatic cancer tissues as well as cancer cells of breast cancer, prostate cancer, and others. Through preclinical studies, STCube discovered that ‘STT-011’ is overexpressed in stromal cells of pancreatic cancer tissues, leading to impaired immune function.

In experiments using the KPC mouse model of pancreatic cancer, STCube proved that suppressing the expression of ‘STT-011’ through gene blockade inhibited cancer cell growth and improved survival rates. In a pancreatic cancer syngeneic transplantation mouse model, administration of ‘SD133’ showed clear anticancer therapeutic effects.

Pancreatic cancer currently has no special treatment methods other than surgical resection and chemotherapy with anticancer drugs such as gemcitabine. Pancreatic cancer is known as one of the most fatal diseases among cancers, with a prognosis that is very poor and a 5-year survival rate of less than 10% after onset.

A company official stated, "After years of joint research with the Lombardi Cancer Center at Georgetown University, we developed the new drug substance ‘SD133’ and plan to conduct clinical trials next year," adding, "Based on the research results conducted so far, we are currently in discussions with major domestic and international pharmaceutical companies for joint development and technology transfer."

This content was produced with the assistance of AI translation services.